CPT code 78227: HIDA scan billing and 2026 rates

Key takeaways

CPT code 78227 covers a hepatobiliary imaging study, or HIDA scan, performed with a pharmacologic agent such as sincalide or morphine.

The only thing separating 78227 from 78226 is a documented pharmacologic intervention, not the length or difficulty of the study.

Medicare’s 2026 national unadjusted amount is roughly $383 global, and about $342 of that sits in the technical component.

Leaving out the agent name, dose, and clinical indication is the most common reason a 78227 claim is denied.

Practice management software like Pabau pre-fills the claim from the record and blocks submission until the required fields are complete.

CPT code 78227 covers a hepatobiliary imaging study, the HIDA scan, performed with a pharmacologic agent such as sincalide or morphine. The drug is the whole distinction. If the report does not show one, the study is CPT 78226 instead.

That one line in the report decides the payment. Medicare’s 2026 national unadjusted amount for 78227 is about $383 globally, and payers downcode or deny when the agent, dose, and indication are missing.

Below you will find the descriptor, the modifier rules, current rates, the ICD-10 codes that support medical necessity, and a pre-submission checklist.

The 78227 descriptor holds four billable elements

The American Medical Association (AMA) maintains CPT code 78227 under the Nuclear Medicine, Diagnostic Procedures section.

The official descriptor reads: Hepatobiliary system imaging, including gallbladder when present; with pharmacologic intervention, including quantitative measurements when performed.

Split into its parts, that sentence tells you what has to be in the record.

The code sits alongside CPT 78226 for hepatobiliary imaging without a drug, and near the liver and spleen imaging codes 78215 and 78216.

The same pattern runs through the whole nuclear medicine family. On CPT 78803, for example, it is the tomographic acquisition that has to be documented rather than assumed.

A HIDA scan only becomes 78227 when a drug is given

A HIDA scan is also called hepatobiliary scintigraphy or cholescintigraphy. It tracks a technetium-99m labeled radiopharmaceutical from the liver through the bile ducts into the small intestine. Depending on the protocol, it runs anywhere from one to four hours.

Pharmacologic intervention comes in when the standard study does not answer the clinical question. Three scenarios account for most of it.

• Sincalide (CCK analog) augmentation: Given to stimulate gallbladder contraction. It is what makes gallbladder ejection fraction (GBEF) possible, and GBEF is the measurement most often attached to 78227.
• Morphine augmentation: Given when the gallbladder has not visualized by 60 minutes while the common bile duct is visualizing and bowel activity is present. Morphine raises sphincter of Oddi resistance and pushes tracer toward the gallbladder. Common in acute cholecystitis protocols.
• Phenobarbital pretreatment: Used in neonatal hepatobiliary studies. It is rare in adult billing, but it supports 78227 when the protocol and the dosing are documented.

Code selection follows the clinical need for the drug. If the nuclear medicine physician ordered the intervention and wrote it down, 78227 applies.

Without that, 78226 is correct no matter how long or complicated the study was. This is a medical necessity distinction, not a reward for a harder scan.

Where coders get 78226 and 78227 mixed up

The pair trips people up constantly. Once you isolate the pharmacologic variable, though, the decision is a single yes or no.

A study that starts as a plain HIDA scan and moves to pharmacologic augmentation partway through is billed as 78227 only.

The drug step is not separately billable, because the descriptor already includes it. Put both codes on the same session and an NCCI edit denies the lower-valued one.

Five details the report needs about the drug

Which agent was used changes the documentation, not the code. Sincalide and morphine both support 78227 when the report is complete.

For each agent given, the physician report has to capture five things:

• Agent name: Use the generic name, so sincalide or morphine sulfate. “CCK analog” on its own fails with payers that ask for specificity.
• Dosage and route: Sincalide is typically infused at 0.02 mcg/kg IV over 60 minutes, morphine at 0.04 mg/kg IV. The dose actually administered belongs in the report.
• Timing against the tracer injection: Place the drug on the imaging timeline, not just in the worksheet.
• Clinical indication for the drug: Say why it was needed, for example “gallbladder not visualized by 60 minutes, morphine augmentation given per protocol”.
• Findings after the intervention: Record how the tracer responded, plus any quantitative result.

GBEF is optional, but document it whenever you calculate it

Quantitative measurement is optional for 78227. The phrase “when performed” in the descriptor gets misread constantly. The code applies because a drug was given, not because gallbladder ejection fraction was calculated.

When GBEF is calculated, record the value, the calculation method, and the interpretation. A result below 35% to 40% is generally treated as abnormal under Society of Nuclear Medicine and Molecular Imaging guidance.

Payer coverage policies set their own thresholds, so check the applicable one. Write the number down rather than leaving it implied.

Modifiers -26 and -TC decide who gets paid what

Modifier choice on 78227 follows the billing arrangement between the interpreting physician and the facility that ran the study.

Modifier -59 draws audit attention. Use it only where the record genuinely supports two distinct services, because CMS treats its misuse as a compliance risk. Reaching for -59 to clear an NCCI edit is how a routine denial turns into audit exposure.

What Medicare pays for CPT 78227 in 2026

Payment for 78227 depends on which component you bill and on your Medicare locality. The amounts below are national unadjusted figures from the Medicare Physician Fee Schedule, so treat them as a starting point.

Confirm your own locality rate with the CMS Physician Fee Schedule lookup tool before you bill.

Every locality applies its own geographic practice cost index, so your allowed amount will move away from these figures.

Commercial rates usually sit above Medicare, but they follow your contract rather than the fee schedule. Check both before you forecast revenue on a HIDA scan volume.

The RVU math behind the 78227 payment

Three components make up the total RVU, and CMS multiplies that total by the conversion factor.

For 2026, CMS finalized a conversion factor of $33.4009 for practices that are not qualifying APM participants. Qualifying participants get $33.5675.

Practice expense carries almost the whole value of this code, which is why the technical component pays roughly eight times the professional component. That also makes a mis-set modifier expensive.

A global claim sent from a hospital outpatient place of service pays only the professional amount. Put the two sets of numbers side by side and the imbalance is hard to miss.

Which ICD-10 codes support a 78227 claim

Medical necessity for 78227 rests on a supported ICD-10-CM diagnosis. Local Coverage Determinations narrow the list further, so confirm coverage with the Medicare Administrative Contractor or the commercial payer handling the claim.

The codes below are the ones that pair with 78227 most often, and none of them guarantees coverage on its own.

What a complete 78227 report has to contain

Thin documentation is the leading cause of 78227 denials, and it is the cheapest problem on this page to fix. A complete nuclear medicine procedure note carries all seven of the following:

• Ordering physician and clinical indication: The referral diagnosis and the reason for the study, recorded before imaging starts.
• Radiopharmaceutical administered: Agent name such as Tc-99m mebrofenin, dose in mCi, route, and time given.
• Pharmacologic agent details: Name, dose, route, infusion time, and timing against the tracer. This is the requirement specific to 78227.
• Imaging protocol and duration: Total imaging time, the views obtained, and any change to the standard protocol.
• Quantitative results when performed: The GBEF value, the method, and the interpretation. If no GBEF was calculated, say so explicitly.
• Physician interpretation: A signed final report with findings, impression, and an answer to the clinical question.
• Complications or adverse reactions: Any reaction to the drug, which also supports separate billing for management where it was clinically significant.

How a 78227 claim moves from scan to payment

Knowing where the claim can break is worth more than knowing the code. Here is the path a 78227 charge takes, and what tends to go wrong at each step:

1. Order and eligibility. The referral arrives with a diagnosis. Eligibility and any prior authorization get checked before the appointment, not on the day.
2. The study. The technologist logs the tracer dose and time, then the drug dose and time. Trouble starts when that detail stays on the worksheet and never reaches the report.
3. The report. The physician dictates findings and names the agent, the dose, the indication, and the GBEF if one was calculated.
4. Charge capture. The coder reads the report, picks 78226 or 78227, adds -26 or -TC to match the setting, and attaches the ICD-10 code.
5. Submission and remittance. The clearinghouse scrubs the claim, the payer adjudicates, and the ERA posts. A CARC code on that remittance tells you which of the four steps above failed.

Six errors that get 78227 claims denied

Denials on this code cluster around a short list of repeat offenders. Learn the list once and you save yourself the rework cycle later.

The reason codes on your remittances point straight at them, and our guide to denial codes maps each one to what needs fixing.

• Coding 78227 without pharmacologic documentation. The most common denial by far. The coder knows a drug was given, but the report has no dedicated intervention line, so the payer downcodes to 78226 and recoups the difference.
• Vague agent details. “CCK given per protocol” is not enough. Payers want the generic name, the dose, the route, and the time, and pre-payment edits at high-volume payers catch the difference.
• Billing 78226 and 78227 for one session. NCCI edits deny the lower-valued code automatically, and no modifier realistically rescues it.
• Stretching modifier -59. Using it to clear an edit when the two services were not genuinely distinct is a documented compliance risk in nuclear medicine.
• An unsupported ICD-10 pairing. A diagnosis outside the payer’s coverage policy fails medical necessity review. Screening Z codes with no biliary complaint rarely pass.
• Place-of-service mismatch. Billing globally for a hospital outpatient study when -26 was correct produces a site-of-service denial.

Run this check before you submit

• The agent name, dose, route, and time appear in the physician report, not only the technologist worksheet.
• The report states why the drug was needed, in words.
• Only one of 78226 and 78227 is on the claim.
• The modifier matches the place of service on the claim line.
• The ICD-10 code on the claim is one the payer’s coverage policy accepts.
• GBEF is recorded with its value and interpretation, or its absence is noted.

How Pabau keeps 78227 claims complete before they go out

Nuclear medicine billing asks a lot of a small team. Studies run for hours, the documentation has several moving parts, and the modifier has to track the setting every single time.

Almost every 78227 denial starts at documentation rather than at submission, which is where software can help.

Pabau, our practice management platform, builds the claim off the record instead of off a worksheet. The CPT code attached to the service lands on the charge line, and ICD-10 slots are seeded from the patient’s recorded problem list.

Coders get CPT, HCPCS, and ICD-10 lookup libraries on the claim itself, so confirming a code does not mean opening another tab.

Pabau’s claims management software then checks that the claim’s required fields are complete before the send button unlocks. Claims route through Claim.MD, a US clearinghouse connected to thousands of payers, with real-time eligibility checks, ERA posting, and claim status tracking.

Your coder still owns the coding decision. The system just stops half-finished claims from leaving the building.

Send cleaner nuclear medicine claims first time

Pabau pre-fills the claim from the patient record and puts CPT and ICD-10 lookup libraries in front of your coders. It also checks that required fields are complete before submission. See how it fits a nuclear medicine workflow.

Book a demo

Conclusion

CPT 78227 is a simple code guarded by one strict piece of documentation. Either the study included a pharmacologic agent or it did not, and the physician report is the only place a payer can see the answer.

So the work sits upstream of billing. Agree with your nuclear medicine physicians on a standing line in every report that names the agent, the dose, the time, and the reason. Once that line becomes habit, 78227 stops being a denial risk and turns into one of the more predictable codes on your remittance.

Book a demo to see how Pabau builds nuclear medicine claims straight from the patient record and holds them until the required fields are complete.

Continue your research

Billing another nuclear medicine study? CPT code 78803 covers SPECT imaging, with its own acquisition and documentation rules.

Need the diagnosis side of a gallbladder claim? ICD-10 code K82.1 walks through hydrops of the gallbladder and the documentation payers look for.

Wondering how a clearinghouse edit catches a bad claim? Medical claims clearinghouse guide explains what pre-submission scrubbing does before a payer ever sees the claim.

Denials piling up across more than one code? Denial management in healthcare sets out a workflow for catching repeat patterns before they become write-offs.

Comparing clearinghouses for a specialty practice? Claim.MD vs Office Ally breaks down the options for teams running high-volume billing.

Frequently asked questions